Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05161598 | Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 16, 2025 | clinicaltrials |
| NCT05503550 | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 16, 2025 |
| clinicaltrials |
| NCT04452994 | Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 | clinicaltrials |
| NCT05238311 | Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | no longer available | — | — | PfizerINDUSTRY | 0 | Feb 4, 2025 | clinicaltrials |
| NCT05462639 | Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma(MAGNETISMM17) | no longer available | — | — | PfizerINDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT02856438 | Early Patient Access Treatment Use Protocol CA204-220 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT02368301 | Expanded Access Treatment Protocol CA204-143 | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 30, 2023 | clinicaltrials |
| NCT03126617 | Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 29, 2021 | clinicaltrials |
| NCT04453397 | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | TeneoOne Inc.INDUSTRY | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02568943 | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 6 | Apr 8, 2020 | clinicaltrials |
| NCT03850704 | Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | no longer available | — | — | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 22, 2019 | clinicaltrials |
| NCT03723096 | Expanded Access for CC-4047 | no longer available | — | — | CelgeneINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT02666209 | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | no longer available | — | — | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT02204553 | Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00799539 | A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients | no longer available | — | — | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00999414 | UARK 2009-32 Compassionate Use Study of Carfilzomib(2009-32) | no longer available | — | — | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT02541643 | Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | Sundar JagannathOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT00063791 | A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE | no longer available | — | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Dec 16, 2025source: clinicaltrials